Vosoritide for Achondroplasia - Another step towards commercialisation in the EU
2021-07-31Research
On June 25, 2021, the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency, EMA, recommended the marketing authorisation of Voxzogo (trade name of vosoritide) in the European Union (EU)...
The Pros and Cons in each different treatment for Achondroplasia
2021-07-14Research
This recent study by Dr. Wiktoria Wrobel (Medical University of Lublin, Poland) brings together the different pharmacological treatments for achondroplasia, both current and potential, highlighting the advantages and disadvantages of each, making it a great comprehensive review.
Assessing the impacts of having a child with achondroplasia on parent well‑being
2021-06-15Research
A paper1 on a Quality of Life research study conducted by Kathryn M. Pfeifer et al aims to develop a better understanding of the experiences of parents of children with achondroplasia.
How does gait differ in children with achondroplasia?
2021-03-12Research
What is still to be understood on how gait in children with achondroplasia is altered compared to average height children.
What is still to be known about achondroplasia
2021-03-12Research
A recently published article by Julie Hoover-Fong et al.1 seeks to synthesize the current knowledge base about the nature, incidence, chronology, and the interrelationships of achondroplasia-related comorbidities across the lifespan.
New potential treatment for achondroplasia by the Tsumaki lab & Astellas Pharma Inc.
2020-12-27Research
The Tsumaki lab, at the Center for iPS Cell Research and Application (CiRA), Kyoto University, is leading new research for achondroplasia with ASP5878, an FGFR inhibitor, using iPS cells. This is a study in collaboration with Astellas Pharma.
